{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:27:45Z","timestamp":1788895665802,"version":"build-2803163510"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Inflammatory myofibroblastic tumor (IMT) of the female genital tract is frequently misdiagnosed as uterine leiomyoma or mesenchymal stromal tumors due to overlapping morphological features.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>A total of 25 cases of IMT were collected between 2019 and 2024 and 8 of them were classified as IMT with unusual features. We conducted a retrospective analysis of 8 cases of unusual features IMT, focusing on histopathological features, immunophenotype, molecular alterations, and clinical follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The misdiagnosis rate is as high as 62.5%. Among these, 3 patients were initially misdiagnosed as uterine leiomyoma; 1 patient was misdiagnosed as low-grade endometrial stromal sarcoma; 1 patient was misdiagnosed as uterine leiomyosarcoma; and 3 patients remained unclear at initial assessment. The patient ranged from 32 to 67 (mean 43) years. Clinically, all presented with uterine masses. Tumors were either solitary or multiple, ranging from 1.2 to 12 cm. Histologically, these tumors exhibited marked heterogeneity with three predominant types, including leiomyoma-like type, myxoid type, and collagenous sclerosis type. 50% of the patients displayed a combination of two or more histologic subtypes. 2 of 8 (25%) patients presented leiomyoma-like morphology; 25% of patients exhibited prominent spiral arteriole proliferation resembling low-grade endometrial stromal sarcoma; 25% of patients occurring during pregnancy presented significant decidual-like changes; and 12.5% of patients resembled epithelioid leiomyosarcoma, characterized by frequent mitotic figures, severe nuclear atypia, prominent nucleoli, and abundant eosinophilic cytoplasm with epithelioid morphology. Immunohistochemical analysis revealed expression of ALK in 62.5% patients. The complete loss of p16 expression was noted in one patient, who was diagnosed as epithelioid inflammatory myofibroblastic sarcoma (EIMS). ALK gene rearrangements were identified by fluorescence in situ hybridization (FISH) on 62.5% patients. All tested cases were positive for ALK rearrangement. During clinical follow-up, 87.5% of patients followed a benign clinical course; the patient of EIMS developed pulmonary and supraclavicular lymph node metastases and remains living with tumor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>EIMS has the ability of invasion and metastasis and presents the abnormal loss of p16. Accurate recognition of IMT with unusual features is crucial for targeted treatment. ALK protein expression and molecular testing play critical roles in diagnosis and differential diagnosis, and lowering the detection threshold to improve sensitivity is urgently needed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1653181","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T04:19:02Z","timestamp":1760588342000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Inflammatory myofibroblastic tumor of female genital tract with unusual features and potential diagnostic pitfalls"],"prefix":"10.3389","volume":"15","author":[{"given":"Huibin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2007.049387","article-title":"Inflammatory myofibroblastic tumours: where are we now","volume":"61","author":"Gleason","year":"2008","journal-title":"J Clin Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199508000-00001","article-title":"Extrapulmonary inflammatory myofibroblastic tumor (Inflammatory pseudotumor) A clinicopathologic and immunohistochemical study of 84 cases","volume":"19","author":"Coffin","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.69","article-title":"Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum","volume":"30","author":"Bennett","year":"2017","journal-title":"Mod Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1461092","article-title":"Uterine inflammatory myofibroblastic tumor: a retrospective analysis","volume":"14","author":"Bai","year":"2024","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00036","article-title":"Inflammatory myofibroblastic tumors in the uterus: childhood-case report and review of the literature","volume":"8","author":"Etlinger","year":"2020","journal-title":"Front Pediatr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e8974","DOI":"10.1097\/MD.0000000000008974","article-title":"Uterine inflammatory myofibroblastic tumor","volume":"96","author":"Mandato","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000172189.02424.91","article-title":"Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors","volume":"29","author":"Rabban","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100143","article-title":"Leiomyoma-like morphology in metastatic uterine inflammatory myofibroblastic tumors","volume":"36","author":"Devins","year":"2023","journal-title":"Mod Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001756","article-title":"Uterine inflammatory myofibroblastic neoplasms with aggressive behavior, including an epithelioid inflammatory myofibroblastic sarcoma: A clinicopathologic study of 9 cases","volume":"46","author":"Collins","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001044","article-title":"Inflammatory myofibroblastic tumor associated with the placenta","volume":"42","author":"Ladwig","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001120","article-title":"ALK is a specific diagnostic marker for inflammatory myofibroblastic tumor of the uterus","volume":"42","author":"Mohammad","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/PGP.0000000000000858","article-title":"ALK immunoexpression is specific for inflammatory myofibroblastic tumor among vulvovaginal mesenchymal neoplasms","volume":"42","author":"Bowman","year":"2023","journal-title":"Int J Gynecol. Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001525","article-title":"Inflammatory myofibroblastic tumor of the uterus: an immunohistochemical study of 23 cases","volume":"44","author":"Bennett","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/PAS.0000000000001083","article-title":"ALK-rearranged tumors are highly enriched in the STUMP subcategory of uterine tumors","volume":"43","author":"Devereaux","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2020.03.014","article-title":"Uterine inflammatory myofibroblastic tumor involving the decidua of the extraplacental membranes: report of a case with a TIMP3-ROS1 gene fusion","volume":"100","author":"Schoolmeester","year":"2020","journal-title":"Hum Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-005142","article-title":"Uterine inflammatory myofibroblastic tumor with myxoid predominance: diagnostic challenge","volume":"34","author":"Rodrigues","year":"2024","journal-title":"Int J Gynecol. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.humpath.2020.09.005","article-title":"Inflammatory myofibroblastic tumors associated with the placenta: a series of 9 cases","volume":"106","author":"Makhdoum","year":"2020","journal-title":"Hum Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000330","article-title":"Inflammatory myofibroblastic tumor of the uterus: clinical and pathologic review of 10 cases including a subset with aggressive clinical course","volume":"39","author":"Parra-Herran","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001987","article-title":"Uterine inflammatory myofibroblastic tumors: proposed risk stratification model using integrated clinicopathologic and molecular analysis","volume":"47","author":"Ladwig","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000909","article-title":"Inflammatory myofibroblastic tumors of the female genital tract are under-recognized: A low threshold for ALK immunohistochemistry is required","volume":"41","author":"Pickett","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30116-4","article-title":"Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial","volume":"6","author":"Sch\u00f6ffski","year":"2018","journal-title":"Lancet Respir Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1653181\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T04:19:02Z","timestamp":1760588342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1653181\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":21,"alternative-id":["10.3389\/fonc.2025.1653181"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1653181","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"article-number":"1653181"}}